Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more
Country of origin

Decoquinate API Manufacturers & Suppliers

2 verified results
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.

Commercial-scale Suppliers

Producer
Produced in  China
|

Employees: 250+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
FDA
|
CEP
|
MSDS
|
CoA

All certificates

GMP
FDA
CEP
MSDS
CoA
Producer
Produced in  China
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
USDMF
|
EDMF/ASMF
|
MSDS
|
BSE/TSE

All certificates

GMP
USDMF
EDMF/ASMF
MSDS
BSE/TSE
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Get full market intelligence report
Get full market intelligence report
€399,-
All Decoquinate data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Decoquinate | CAS No: 18507-89-6 | GMP-certified suppliers

A medication that controls gastrointestinal coccidial infections in livestock, supporting parasite growth inhibition and prevention of coccidiosis in veterinary applications.

Therapeutic categories

Anti-Infective AgentsAntiparasitic AgentsAntiprotozoalsCoccidiostatsHeterocyclic Compounds, Fused-RingHydroxyquinolines
Generic name
Decoquinate
Molecule type
small molecule
CAS number
18507-89-6
DrugBank ID
DB11394
Approval status
Experimental drug, Vet_approved drug

Product Snapshot

  • Decoquinate is formulated as a powder intended for veterinary use
  • Its primary application is as an anticoccidial agent in animal health
  • The compound is approved for veterinary use but remains experimental in human markets

Clinical Overview

Decoquinate (CAS Number 18507-89-6) is a veterinary antimicrobial agent primarily used to inhibit the growth and reproduction of coccidian parasites. It belongs to the chemical class of hydroquinolones, characterized by a hydrogenated quinoline structure containing a ketone group.

Decoquinate acts as a coccidiostat, specifically targeting protozoal parasites that affect the gastrointestinal tract of livestock species. While detailed pharmacodynamic parameters and precise mechanisms of action are not fully elucidated, its primary function is to interfere with the lifecycle of coccidia organisms, thereby controlling infection and reducing parasite load without directly causing parasite death.

Hepatic metabolism and pharmacokinetic data, including absorption, distribution, metabolism, and excretion (ADME) parameters, are not comprehensively described in the available literature. Its clinical use is predominantly restricted to veterinary applications, where it forms part of anti-infective and antiparasitic treatment regimens.

Safety and toxicity data for decoquinate emphasize its veterinary approval status; however, specific human safety profiles are unavailable given its use is limited to non-human species. The compound’s toxicity in animals requires adherence to recommended dosing protocols to minimize adverse effects, and withdrawal times must be observed to ensure no residues persist in food products derived from treated animals.

Notable formulations containing decoquinate are used in the prevention and management of coccidiosis in poultry, cattle, and other livestock, making it a valuable agent in veterinary parasitology.

From an API sourcing perspective, ensuring the purity and consistent physicochemical quality of decoquinate is critical due to its role in animal health. Manufacturers and procurement professionals should verify compliance with veterinary pharmaceutical standards and regulatory requirements to support safe and effective formulation development.

Identification & chemistry

Generic name Decoquinate
Molecule type Small molecule
CAS 18507-89-6
UNII 534I52PVWH
DrugBank ID DB11394

Formulation & handling

  • Decoquinate is a lipophilic small molecule with low water solubility, indicating potential challenges in oral formulation dissolution.
  • Its chemical stability profile is not detailed, but handling should consider low aqueous solubility and possible formulation strategies to enhance bioavailability.
  • Given its veterinary approval and experimental status, it is primarily intended for non-injectable (oral) administration in animal health.

Regulatory status

Decoquinate is a type of Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.

Decoquinate API manufacturers & distributors

Compare qualified Decoquinate API suppliers worldwide. We currently have 2 companies offering Decoquinate API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Producer
China China BSE/TSE, CoA, EDMF/ASMF, GMP, MSDS, USDMF235 products
Producer
China China CEP, CoA, FDA, GMP, MSDS12 products

When sending a request, specify which Decoquinate API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Decoquinate API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.